With Type 1 Diabetes Delay Possible, Focus Now on Screening

The FDA approval of teplizumab for the delay of type 1 diabetes highlights the need to cost-effectively identify those at risk who could potentially receive it.

Related Keywords

Colorado , United States , Germany , Washington , United Kingdom , Denver , Seattle , Aaron Kowalski , Jason Hoitt , Williama Hagopian , Provention Bio , Pacific Northwest Research Institute , Human Services , Drug Administration , Us Department Of Health , Screening Panel , Medscape Medical News , Would Screening , Western Europe , Medscape Medical , Washington State , Recommended Uniform Screening Panel , Two Pronged Approach , Screening Could Work , Diabetes Mellitus Type 1 , Iabetes Mellitus Type I , Type 1 Diabetes , Preventive Screening , Screening , Children , Child , Childhood , Ediatrics , Kids , Newborn , Neonate , Newborn Screening , Genetics , Genomics , Genomic Medicine , Edicine Genomic , Pregnancy , Human Leukocyte Antigen , La Human Leukocyte Antigen , Biologic Therapy , Immunotherapy , Monoclonal Antibody , Etuximab , Ituximab , United Kingdom Site Conten ,